Published in PLoS Pathog on June 14, 2012
Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. PLoS Pathog (2015) 1.61
New generation humanized mice for virus research: comparative aspects and future prospects. Virology (2013) 1.38
Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog (2014) 1.32
Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rγ(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells. Clin Exp Immunol (2013) 1.13
Macrophages sustain HIV replication in vivo independently of T cells. J Clin Invest (2016) 1.04
BLT humanized mice as a small animal model of HIV infection. Curr Opin Virol (2015) 1.00
Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants. Retrovirology (2013) 0.98
Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk. Proc Natl Acad Sci U S A (2013) 0.96
The role of cell-associated virus in mother-to-child HIV transmission. J Infect Dis (2014) 0.95
Overcoming current limitations in humanized mouse research. J Infect Dis (2013) 0.95
HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model. Retrovirology (2013) 0.93
Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice. PLoS One (2013) 0.93
Humanized mice for the study of infectious diseases. Curr Opin Immunol (2013) 0.92
Breast Milk of HIV-Positive Mothers Has Potent and Species-Specific In Vivo HIV-Inhibitory Activity. J Virol (2015) 0.86
An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8+ T cells in mice. PLoS One (2014) 0.85
Studies of retroviral infection in humanized mice. Virology (2015) 0.83
In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. Retrovirology (2016) 0.80
ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions. J Clin Invest (2016) 0.80
Hypogammaglobulinemia in BLT humanized mice--an animal model of primary antibody deficiency. PLoS One (2014) 0.80
In vivo platforms for analysis of HIV persistence and eradication. J Clin Invest (2016) 0.80
Role of Semen on Vaginal HIV-1 Transmission and Maraviroc Protection. Antimicrob Agents Chemother (2015) 0.79
Humanized mouse models for HIV-1 infection of the CNS. J Neurovirol (2014) 0.79
HIV-specific CD8⁺ T-cell immunity in humanized bone marrow-liver-thymus mice. J Infect Dis (2013) 0.77
HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection. J Antimicrob Chemother (2016) 0.77
Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA. PLoS One (2016) 0.77
Engineering a Therapeutic Lectin by Uncoupling Mitogenicity from Antiviral Activity. Cell (2015) 0.77
CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice. Mol Ther Oncolytics (2016) 0.76
The Presence and Anti-HIV-1 Function of Tenascin C in Breast Milk and Genital Fluids. PLoS One (2016) 0.75
E. E. Just Award lecture. Mol Biol Cell (2013) 0.75
Critical need for appropriate mucosal sample collection to determine relational animal pharmacokinetic-pharmacodynamic models in HIV prevention. AIDS Res Hum Retroviruses (2013) 0.75
In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies. J Infect Dis (2017) 0.75
Mother-to-Child HIV-1 Transmission Events Are Differentially Impacted by Breast Milk and Its Components from HIV-1-Infected Women. PLoS One (2015) 0.75
HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy. Nat Med (2017) 0.75
Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. Sci Rep (2017) 0.75
Mucus and Mucins: do they have a role in the inhibition of the human immunodeficiency virus? Virol J (2017) 0.75
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet (2004) 16.28
Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science (1987) 12.77
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med (2010) 8.51
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med (2008) 5.81
Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med (2006) 5.36
Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr (2009) 4.82
Immunity, inflammation, and allergy in the gut. Science (2005) 4.82
Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol (1999) 4.66
Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med (2007) 3.75
Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis (2000) 3.02
Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest (1995) 2.95
Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol (2009) 2.70
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol (2011) 2.55
Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS (1996) 2.41
Generation of HIV latency in humanized BLT mice. J Virol (2011) 2.20
Infective and anti-infective properties of breastmilk from HIV-1-infected women. Lancet (1993) 2.18
Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis (1995) 2.16
Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One (2010) 1.88
Dendritic cells in intestinal homeostasis and disease. J Clin Invest (2009) 1.83
Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis (2005) 1.82
Cell-free human immunodeficiency virus type 1 in breast milk. J Infect Dis (1998) 1.74
Human immunodeficiency virus type 1-infected cells in breast milk: association with immunosuppression and vitamin A deficiency. J Infect Dis (1995) 1.62
Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission. Rev Med Virol (2007) 1.52
Some aspects of gastric function in the newborn. Arch Dis Child (1962) 1.52
Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J Acquir Immune Defic Syndr (2006) 1.38
Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis (2003) 1.36
HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS (2008) 1.36
Intestinal effector T cells in health and disease. Immunity (2009) 1.24
Identifying and characterizing recently transmitted viruses. Curr Opin HIV AIDS (2010) 1.19
Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. J Virol (2005) 1.19
Endogenous mucosal antiviral factors of the oral cavity. J Infect Dis (1999) 1.18
Barriers to mucosal transmission of immunodeficiency viruses. Blood (2011) 1.14
Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. Virology (2010) 1.13
The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. J Virol (2011) 1.10
IL-2 receptor γ-chain molecule is critical for intestinal T-cell reconstitution in humanized mice. Mucosal Immunol (2012) 1.09
MUC1 in human milk blocks transmission of human immunodeficiency virus from dendritic cells to T cells. Mol Immunol (2009) 1.06
Bile salt-stimulated lipase from human milk binds DC-SIGN and inhibits human immunodeficiency virus type 1 transfer to CD4+ T cells. Antimicrob Agents Chemother (2006) 1.06
The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted viruses. J Virol (2008) 1.02
Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral epithelia. J Virol (2011) 0.99
Long-chain n-6 polyunsaturated fatty acids in breast milk decrease the risk of HIV transmission through breastfeeding. Am J Clin Nutr (2007) 0.95
Quantification and distribution of lymphocyte subsets and Langerhans cells in normal human oral mucosa and skin. J Oral Pathol Med (1989) 0.92
Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. AIDS Res Hum Retroviruses (1996) 0.92
Inhibition of human immunodeficiency virus type 1 activity by purified human breast milk mucin (MUC1) in an inhibition assay. Neonatology (2007) 0.92
Lymphocytes and Langerhans cells in the human oesophageal epithelium. Virchows Arch A Pathol Anat Histopathol (1983) 0.92
Innate factors in human breast milk inhibit cell-free HIV-1 but not cell-associated HIV-1 infection of CD4+ cells. J Acquir Immune Defic Syndr (2009) 0.90
Binding of human milk to pathogen receptor DC-SIGN varies with bile salt-stimulated lipase (BSSL) gene polymorphism. PLoS One (2011) 0.86
Human immunodeficiency virus type 1 RNA in breast-milk components. J Infect Dis (2003) 0.84
Detection of HIV-1 in Saliva: Implications for Case-Identification, Clinical Monitoring and Surveillance for Drug Resistance. Open Virol J (2010) 0.83
Failure to detect active virus replication in mast cells at various tissue sites of HIV patients by immunohistochemistry. Int J Biol Sci (2009) 0.81
Long-chain polyunsaturated fatty acids as anti-HIV supplementation during breastfeeding. Taiwan J Obstet Gynecol (2009) 0.79
Assessment of oral transmission using cell-free human immunodeficiency virus-1 in mice reconstituted with human peripheral blood leucocyte. Immunology (2003) 0.77
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med (2008) 5.81
Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med (2006) 5.36
Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med (2007) 3.75
Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature (2009) 3.18
Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc Natl Acad Sci U S A (2004) 2.75
Role of Peyer's patches in the induction of Helicobacter pylori-induced gastritis. Proc Natl Acad Sci U S A (2007) 2.44
Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol (2002) 2.43
Generation of HIV latency in humanized BLT mice. J Virol (2011) 2.20
Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. J Clin Invest (2013) 2.15
Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J Virol (2005) 2.05
Dengue fever in humanized NOD/SCID mice. J Virol (2005) 1.96
HIV-1 Nef: at the crossroads. Retrovirology (2008) 1.88
Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One (2010) 1.88
Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model. Cell Host Microbe (2010) 1.77
Serum 25-hydroxyvitamin D in a West African population of tuberculosis patients and unmatched healthy controls. Am J Clin Nutr (2007) 1.77
RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol (2009) 1.73
Production of transgenic rats by lentiviral transduction of male germ-line stem cells. Proc Natl Acad Sci U S A (2002) 1.68
Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibody-mediated symbiosis. Proc Natl Acad Sci U S A (2010) 1.67
Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. PLoS Pathog (2015) 1.61
Intracellularly expressed TLR2s and TLR4s contribution to an immunosilent environment at the ocular mucosal epithelium. J Immunol (2004) 1.60
Comprehensive gene expression profiling of Peyer's patch M cells, villous M-like cells, and intestinal epithelial cells. J Immunol (2008) 1.58
Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans. Hum Genet (2009) 1.45
Dynamic evolution of the human immunodeficiency virus type 1 pathogenic factor, Nef. J Virol (2006) 1.41
Nef: agent of cell subversion. Microbes Infect (2002) 1.41
Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J Virol (2007) 1.40
Novel humanized murine models for HIV research. Curr HIV/AIDS Rep (2009) 1.40
Specific expression of apolipoprotein A-IV in the follicle-associated epithelium of the small intestine. Dig Dis Sci (2014) 1.38
Molecular mechanisms of autosomal recessive hypercholesterolemia. Hum Mol Genet (2002) 1.33
Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble. Nat Chem Biol (2011) 1.31
Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. J Virol (2004) 1.24
Human dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors. Blood (2003) 1.23
Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. J Reprod Immunol (2011) 1.22
Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat Commun (2012) 1.18
Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol (2012) 1.15
Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes. Retrovirology (2012) 1.14
Development and activation of human dendritic cells in vivo in a xenograft model of human hematopoiesis. Stem Cells (2005) 1.14
Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine. Proc Natl Acad Sci U S A (2010) 1.11
Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse. J Virol (2011) 1.11
Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1. J Virol (2012) 1.10
A hydrophobic binding surface on the human immunodeficiency virus type 1 Nef core is critical for association with p21-activated kinase 2. J Virol (2006) 1.10
Mechanisms of HIV-1 Nef function and intracellular signaling. J Neuroimmune Pharmacol (2011) 1.04
Macrophages sustain HIV replication in vivo independently of T cells. J Clin Invest (2016) 1.04
Id2-, RORgammat-, and LTbetaR-independent initiation of lymphoid organogenesis in ocular immunity. J Exp Med (2009) 1.04
Immunological commonalities and distinctions between airway and digestive immunity. Trends Immunol (2008) 1.01
Peyer's patches are required for intestinal immunoglobulin A responses to Salmonella spp. Infect Immun (2007) 1.01
HIV restriction by APOBEC3 in humanized mice. PLoS Pathog (2013) 1.00
Role of Nef in HIV-1 replication and pathogenesis. Adv Pharmacol (2007) 1.00
In vivo analysis of Nef function. Curr HIV Res (2003) 1.00
Distinct fucosylation of M cells and epithelial cells by Fut1 and Fut2, respectively, in response to intestinal environmental stress. Biochem Biophys Res Commun (2010) 0.97
M cells expressing the complement C5a receptor are efficient targets for mucosal vaccine delivery. Eur J Immunol (2011) 0.97
Cryptopatches are essential for the development of human GALT. Cell Rep (2013) 0.96
Bone marrow-derived cells contribute to contractile dysfunction in endotoxic shock. Am J Physiol Heart Circ Physiol (2004) 0.96
Antigen-sampling cells in the salmonid intestinal epithelium. Dev Comp Immunol (2010) 0.94
HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. J Virol (2014) 0.94
Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains. AIDS Res Hum Retroviruses (2012) 0.93
Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice. PLoS One (2013) 0.93
New horizon of mucosal immunity and vaccines. Curr Opin Immunol (2009) 0.93
NFIL3-deficient mice develop microbiota-dependent, IL-12/23-driven spontaneous colitis. J Immunol (2014) 0.92
Activation of p21-activated kinase 2 by human immunodeficiency virus type 1 Nef induces merlin phosphorylation. J Virol (2005) 0.92
CD4 and MHC-I downregulation are conserved in primary HIV-1 Nef alleles from brain and lymphoid tissues, but Pak2 activation is highly variable. Virology (2006) 0.92
Inefficient vaginal transmission of tenofovir-resistant HIV-1. J Virol (2012) 0.91
Broad-range real time PCR and DNA sequencing for the diagnosis of bacterial meningitis. Scand J Infect Dis (2006) 0.91
Induction of toxin-specific neutralizing immunity by molecularly uniform rice-based oral cholera toxin B subunit vaccine without plant-associated sugar modification. Plant Biotechnol J (2013) 0.91
The airway antigen sampling system: respiratory M cells as an alternative gateway for inhaled antigens. J Immunol (2011) 0.90
Functional characterization of the human immunodeficiency virus type 1 Nef acidic domain. J Virol (2008) 0.89
Murine colitis is mediated by vimentin. Sci Rep (2013) 0.89
Interleukin 12B (IL12B) genetic variation and pulmonary tuberculosis: a study of cohorts from The Gambia, Guinea-Bissau, United States and Argentina. PLoS One (2011) 0.88
A cluster of virus-encoded microRNAs accelerates acute systemic Epstein-Barr virus infection but does not significantly enhance virus-induced oncogenesis in vivo. J Virol (2013) 0.87
Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun (2013) 0.87
In vivo analysis of highly conserved Nef activities in HIV-1 replication and pathogenesis. Retrovirology (2013) 0.86
Overlapping effector interfaces define the multiple functions of the HIV-1 Nef polyproline helix. Retrovirology (2012) 0.85
The HIV-1 Vif protein mediates degradation of Vpr and reduces Vpr-induced cell cycle arrest. DNA Cell Biol (2008) 0.85
Self-association of the Lentivirus protein, Nef. Retrovirology (2010) 0.84
Oral MucoRice expressing double-mutant cholera toxin A and B subunits induces toxin-specific neutralising immunity. Vaccine (2009) 0.84
Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs). Antiviral Res (2011) 0.83
In vivo fluorescent labeling of corneal wound healing fibroblasts. Exp Eye Res (2003) 0.83
Reconstitution and molecular analysis of an active human immunodeficiency virus type 1 Nef/p21-activated kinase 2 complex. J Virol (2005) 0.83
RNAi suppression of rice endogenous storage proteins enhances the production of rice-based Botulinum neutrotoxin type A vaccine. Vaccine (2012) 0.82
HIV pathogenesis: Nef loses control. Cell (2006) 0.81
HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. AIDS (2016) 0.81
Progress towards an AIDS mucosal vaccine: an overview. Tuberculosis (Edinb) (2007) 0.80